Advances in Anticoagulant and Antiplatelet Therapy for Coronary Artery Disease

Dear Colleagues,

Coronary heart disease (CAD) is one of the most threatening cardiovascular diseases to human health. How to choose the best antithrombotic regimen has always been the focus of clinical research. Antiplatelet drug cyclooxygenase inhibitor aspirin and adenosine diphosphate P2Y12 receptor blockers are currently the pillars for the prevention and treatment of cardiovascular and cerebrovascular diseases, especially in patients treated with coronary stenting.

Patients requiring combined anticoagulation and antiplatelet therapy are clinically difficult to manage, and the management of CAD patients with complex clinical features remains demanding due to the risk of ischemic and bleeding events, due to multiple comorbidities and/or complex interventional procedures. There is often a high risk associated, and the pros and cons of this intensive antithrombotic therapy need to be weighed. Therefore, consensus and clinical updates on antithrombotic therapy in patients with acute coronary syndrome and/or percutaneous coronary intervention needing oral anticoagolation, such as those with atrial fibrillation, are particularly important.

This Special Issue focuses on the problems in the clinical practice of anticoagulation and antiplatelet therapy in patients with different types of CAD and CAD complicated with AF, which is of great significance for guiding clinicians in diagnosis and treatment. We welcome contributions to these and related topics, including original research and commentary to inform readers of the latest progress.

Dr. Giuseppe De Luca
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the Special Issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.